Connect

Research and connection bring hope to rare disease patients and families

2022年2月25日

Peter Linsley, Kerry Holland別

In recognition of #RareDiseaseDay, Elsevier is making select research articles and book chapters freely available for two months

As the mother of a boy with a rare congenital heart defect, Elsevier’s Melanie Tucker talks about the value of community for patients, caregivers and researchers. Melanie is a Senior Content Strategist for Elsevier’s Neurology, Radiology, Psychiatry and Sleep Medicine books program. In her 20th week of pregnancy, Melanie Tucker went for a routine ultrasound. What followed was anything but routine. Melanie and her husband learned of their son’s diagnosis: Tetralogy of Fallot 新しいタブ／ウィンドウで開く — a complex congenital heart defect that occurs in about 1 in every 3,000 births.

Since his birth, Melanie’s son has undergone multiple surgeries and procedures, and will be followed closely by cardiologists as he gets older. “As parents,” Melanie said, “it is heartbreaking to see your children endure any pain.”

You just want them to lead healthy and happy lives. Our son is the bravest and strongest little boy, and my husband and I are always in awe of his tenacity and strength. Although we have to take certain precautions, especially during COVID, and he has doctor appointments and procedures, he is a happy little boy attending Pre-K and loves coloring, reading and playing.

Now, Melanie, a Senior Content Strategist at Elsevier for Elsevier’s Neurology, Radiology, Psychiatry and Sleep Medicine books program, has a message for other families and patients who are beginning their journey with a rare disease diagnosis:

Although it is scary, please know you are not alone.

Throughout their experience with rare disease, connecting with others has made all the difference in their outlook: “There are communities of patients and parents who understand exactly what you are going through. They can offer advice, support, and share their experiences.” Dedicated organizations also provide additional resources and community, while research brings hope for new and less-invasive treatments.

Although Melanie and her family received an early diagnosis, this is not always the case for rare disease patients.

"Every genome we analyze in the lab is, in reality, a person ..."

Dr Claudia Gonzaga-Jauregui 新しいタブ／ウィンドウで開く is a Principal Investigator in genomics at the International Laboratory for Human Genome Research at the National Autonomous University of Mexico (UNAM) 新しいタブ／ウィンドウで開く. She earned her PhD in Molecular and Human Genetics from Baylor College of Medicine 新しいタブ／ウィンドウで開く, where she contributed to large population genomic studies and pioneered the analyses of genomic sequencing data for the identification of disease genes and molecular diagnoses.

One of Claudia’s first patient interactions was to communicate the result of a SYNGAP1 variant in a boy that had been a medical mystery for a long time:

I met the boy and his mom, and seeing the people behind the data I had analyzed in the lab — and the emotion of the mom when receiving the result of the genomic study, finally having an answer for her child after many years — was very meaningful and impactful. It emphasized how every genome that we analyze in the lab is, in reality, a person that is struggling with a disease and waiting for an answer.

Since leaving Baylor and returning to Mexico, Claudia has dedicated her career to the study and identification of novel genes responsible for rare genetic disorders, to provide answers to patients with undiagnosed diseases. For Claudia, connection and collaboration drive her rare disease work:

I think the rare disease community realized very early on that we needed to work together to find answers for our patients. … We had one patient with a very likely new disease gene, but we needed to find other patients to be sure. Finding the second or third or more patients for a completely new condition is motivating because it means that there are, and likely will be, more patients elsewhere in the world, and perhaps our findings and publications will help get those other patients diagnosed faster and open opportunities for therapy development.

Research on rare diseases

Claudia is one of dozens of authors whose work Elsevier has made freely available for 60 days beginning on Rare Disease Day 新しいタブ／ウィンドウで開く February 28. Content includes Clinics 新しいタブ／ウィンドウで開く review articles and articles and chapters in our books and journals 新しいタブ／ウィンドウで開く, including the Cell Press 新しいタブ／ウィンドウで開く portfolio — all intended to support researchers and clinicians in identifying the molecular basis of these diseases, advancing drug discovery and drug repurposing efforts, translating findings to the clinic, and counseling patients and families.

Articles from Elsevier’s Clinics and books detail a range of specific diseases, from rare congenital malformations to neurological disorders.

Rare diseases, by definition, affect a small number of individuals compared to the general population. In the United States, a disease is called rare if it affects fewer than 200,000 people at any given time 新しいタブ／ウィンドウで開く. In Europe, the ratio is 1 affected person in 2,000 新しいタブ／ウィンドウで開く. The total number of known, named rare diseases worldwide falls somewhere between 6,000 and 8,000 conditions. Although each individual disease is uncommon, their collective prevalence is estimated at 6 percent to 8 percent of the world population, implying that 450 million people have a rare disease 新しいタブ／ウィンドウで開く.

In other words, rare diseases are not as rare as they seem.

“It always comes down to the human aspect.”

Dr Donald G Basel 新しいタブ／ウィンドウで開く, Section Chief, Professor and Associate Director of the Undiagnosed & Rare Diseases, Genomic Sciences and Precision Medicine Center at Children’s Wisconsin 新しいタブ／ウィンドウで開く, has been working in genetics for 22 years.

Regardless of whether conditions are obscure or occur more frequently, he said:

It always comes down to the human aspect — that connectedness where you feel the bond between patient and doctor and the ‘rightness’ of the research outcome that you know will drive future thinking.

Dr Basel and his mentor, Dr Robert Kliegman 新しいタブ／ウィンドウで開く, Chair Emeritus of Pediatrics at the Medical College of Wisconsin and Editor of the Nelson Textbook of Pediatrics 新しいタブ／ウィンドウで開く, are motivated by their mantra: “None of us are as smart as all of us.” It drives home that treating rare diseases is a team sport and everyone’s strengths contribute to the overall outcome of patients.

Further, this inter-connectedness of researchers and clinicians in the rare disease community plays a crucial part in ensuring access to medical evaluation.

Dr Brett J Bordini 新しいタブ／ウィンドウで開く, a founding member of the Medical College of Wisconsin’s rare disease evaluation service along with Dr Kliegman, believes that the future of rare disease research and clinical care is going to require making sure that this wider availability is paired with a strong focus on equity in terms of access:

Enhanced broad network building paired with the ongoing development of localized evaluation teams can help ensure better equity with respect to diagnostic access and can ensure that everyone has an equal opportunity to attain diagnosis for their rare disorder.